Research Article
BibTex RIS Cite

Vajinal Pap-Smear Test Sonucu Atrofi Olan Hastaların Klinik Özelliklerinin Değerlendirilmesi

Year 2021, Volume: 5 Issue: 2, 132 - 136, 29.05.2021
https://doi.org/10.29058/mjwbs.767211

Abstract

Amaç: Serviksteki prekanseröz değişiklikleri saptamak için kullanılan pap-smear testi hormonal durum hakkında da bilgi verebilir. Vajinal atrofi kadınlarda birçok şikâyete sebep olarak yaşam kalitesini etkileyebilir. Çalışmada pap-smear testinde atrofi saptanan hasta grubunda yaş, semptom, menopoz durumu ve ultrasonografi ile ölçülen endometrial kalınlık ilişkisini incelemek amaçlandı.
Gereç ve Yöntemler: Pap-smear testi yapılıp sonucunda atrofi saptanan hastalar çalışmaya alındı. Hastaların yaş, semptom, menopoz durumu ve ultrasonografi ile ölçülen endometrial kalınlıkları dosyalardan taranarak elde edildi ve aralarındaki ilişki istatiksel olarak incelendi.
Bulgular : Toplam 408 hastanın 86’sında (%21,1) semptom görüldü. En sık görülen semptom disüri, üriner inkontinans idi. Semptomları olanların yaş ortalaması 55,8±10,9 iken, semptomları olmayanların yaş ortalaması 53,2±9,9 idi ve aralarında anlamlı fark vardı (p=0,038). Menopozda olan hastaların 70’inde (%23,7) semptom görülürken, menopozda olmayan hastaların 16’sında (%14,2) semptom görüldü. Menopozda olan hastalarda olmayanlara göre istatiksel olarak anlamlı bir şekilde semptomların olduğu görüldü (p=0,041). Postmenopozal dönemde olan hastalarda ultrasonografi ile ölçülen endometrial kalınlık ortalaması semptomu olmayanlarda 4,74±3,64 iken semptomu olan hastalarda 3,54±1,17 idi. Aralarında istatiksel olarak anlamlı fark saptandı (p <0,001).
Sonuç: Pap-smearde saptanan atrofi durumunda, özellikle postmenopozal dönemde ve ileri yaşta, hasta şikâyet belirtmese dâhi hayat kalitesini etkileyen vulvavajinal atrofi semptomları açısından sorgulanmalıdır. Ayrıca ultrasonogrofide endometrial kalınlığı daha ince saptanan postmenopozal hasta grubunda bu semptomlar açısından daha da dikkatli olunmalıdır.

References

  • 1. Lauritzen C. Basic facts and definitions. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. pp 3–8
  • 2. Gandhi J., Chen A., Dagur G., Suh Y., Smith N., Cali B., Khan S.A. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am. J. Obstet. Gynecol. 2016;215:704–711.
  • 3. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–8.
  • 4. Robinson D, Cardozo L. Estrogens and urogenital atrophy. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. 205–18.
  • 5. Crothers BA, Booth CN, Darragh TM, Means MM, Souers RJ, Thomas N, Moriarty AT. Atrophic vaginitis: concordance and interpretation of slides in the College of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology. Arch Pathol Lab Med. 2012;136(11):1332-8.
  • 6. Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC. Vaginal Health in Menopausal Women. Medicina (Kaunas). 2019 Sep 20;55(10):615.
  • 7. Repse-Fokter A, Takac I, Fokter SK. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause. Gynecol Endocrinol. 2008;24(7):399-404.
  • 8. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet. Gynecol. 2008;111(1):127–36.
  • 9. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387-395.
  • 10. Gass ML, Cochrane BB, Larson JC et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women’s Health Initiative. Menopause 2011;18(11):1160–71.
  • 11. Domoney C. Treatment of vaginal atrophy. Womens Health (Lond) 2014;10(2):191-200.
  • 12. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views and attitudes (VIVA) – results from an international survey. Climacteric 2012;15(1):36–44.
  • 13. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Womens Views of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex. Med. 2013;10(7):1790–9.
  • 14. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168–82.
  • 15. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J. Sex. Med. 2009;6(8):2133–42.
  • 16. Kaaks R, Lukanova A, Kurzer MS. Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531-43.
  • 17. H Jamal, H Saygılı, SE Akhan, A Kartal et al. Asemptomatik Postmenopozal Kadınlarda Periferik Androjenlerin, Seks Hormonu Bağlayıcı Globülinin ve Vücut Kitle indeksinin Ultrasonografide Endometrium Kalınlığına Etkileri. İstanbul Tıp Dergisi 2004;4:13-9.
Year 2021, Volume: 5 Issue: 2, 132 - 136, 29.05.2021
https://doi.org/10.29058/mjwbs.767211

Abstract

References

  • 1. Lauritzen C. Basic facts and definitions. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. pp 3–8
  • 2. Gandhi J., Chen A., Dagur G., Suh Y., Smith N., Cali B., Khan S.A. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am. J. Obstet. Gynecol. 2016;215:704–711.
  • 3. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–8.
  • 4. Robinson D, Cardozo L. Estrogens and urogenital atrophy. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. 205–18.
  • 5. Crothers BA, Booth CN, Darragh TM, Means MM, Souers RJ, Thomas N, Moriarty AT. Atrophic vaginitis: concordance and interpretation of slides in the College of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology. Arch Pathol Lab Med. 2012;136(11):1332-8.
  • 6. Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC. Vaginal Health in Menopausal Women. Medicina (Kaunas). 2019 Sep 20;55(10):615.
  • 7. Repse-Fokter A, Takac I, Fokter SK. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause. Gynecol Endocrinol. 2008;24(7):399-404.
  • 8. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet. Gynecol. 2008;111(1):127–36.
  • 9. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387-395.
  • 10. Gass ML, Cochrane BB, Larson JC et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women’s Health Initiative. Menopause 2011;18(11):1160–71.
  • 11. Domoney C. Treatment of vaginal atrophy. Womens Health (Lond) 2014;10(2):191-200.
  • 12. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views and attitudes (VIVA) – results from an international survey. Climacteric 2012;15(1):36–44.
  • 13. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Womens Views of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex. Med. 2013;10(7):1790–9.
  • 14. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168–82.
  • 15. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J. Sex. Med. 2009;6(8):2133–42.
  • 16. Kaaks R, Lukanova A, Kurzer MS. Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531-43.
  • 17. H Jamal, H Saygılı, SE Akhan, A Kartal et al. Asemptomatik Postmenopozal Kadınlarda Periferik Androjenlerin, Seks Hormonu Bağlayıcı Globülinin ve Vücut Kitle indeksinin Ultrasonografide Endometrium Kalınlığına Etkileri. İstanbul Tıp Dergisi 2004;4:13-9.
There are 17 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Research Article
Authors

Anıl Turhan Çakır 0000-0001-7976-4123

Publication Date May 29, 2021
Acceptance Date March 9, 2021
Published in Issue Year 2021 Volume: 5 Issue: 2

Cite

Vancouver Turhan Çakır A. Vajinal Pap-Smear Test Sonucu Atrofi Olan Hastaların Klinik Özelliklerinin Değerlendirilmesi. Med J West Black Sea. 2021;5(2):132-6.

Medical Journal of Western Black Sea is a scientific publication of Zonguldak Bulent Ecevit University Faculty of Medicine.

This is a refereed journal, which aims at achieving free knowledge to the national and international organizations and individuals related to medical sciences in publishedand electronic forms.

This journal is published three annually in April, August and December.
The publication language of the journal is Turkish and English.